Category: Partners

Innovative Asset Monitoring Technology Selected by U.S.’s Largest Container Chassis Provider

WATERLOO, ON / ACCESS Newswire / May 22, 2025 / BlackBerry Limited (NYSE:BB)(TSX:BB) today announced that Direct ChassisLink, Inc. (“DCLI”), the largest provider of container chassis to the U.S. intermodal industry, will deploy BlackBerry® Radar® across 100,000 of its DCL53 domestic 53-foot chassis. The rollout is part of a major initiative DCLI is undertaking to enhance the quality, reliability, visibility and operational efficiency of its fleet, with a view to setting a new freight industry standard for data driven decision-making.

The deployment represents a deepening in the companies’ technological collaboration. DCLI has utilized Radar devices on a subset of its fleet for over five years and after seeing the reliability and intelligence they provide, decided to exponentially increase the number of its chassis deployed with the solution while also recognizing Radar as a top tier supplier.

With the BlackBerry Radar asset monitoring solution, DCLI will gain operational visibility, enabling its customers to optimize asset utilization and deliver more streamlined operations. Thanks to the steady stream of near real-time information Radar provides, DCLI will benefit from precise asset tracking, advanced inventory insights, location-based alerts, and optimized driver and terminal efficiency. Integrated sensors will streamline billing processes and enhance fleet optimization, enabling real-time monitoring of chassis to reduce delays and improve logistics planning.

The rollout of the technology also reinforces DCLI’s commitment to fleet safety and reliability by improving maintenance visibility and response times. This includes preparedness for chassis requiring FMCSA inspections, optimized maintenance scheduling, and enhanced responsiveness for road service – all measures that help minimize downtime, assist with compliance, and help create a safer operating environment for all stakeholders.

“At a time where the freight industry continues to grapple with driver shortages, rising costs, and supply chain disruptions, the need for advanced asset visibility with enhanced fleet management solutions has never been more important,” said Christopher Plaat, SVP and GM of BlackBerry Radar. “With the deployment of Radar, DCLI is taking a vital step in its digital transformation efforts. To that end, we’re excited to demonstrate the countless data-driven insights that can be unlocked when you have improved visibility into the status of your chassis. We look forward to continually improving our platform based on customer use cases and feedback.”

“At DCLI, quality is a top priority, and this initiative reflects our dedication to delivering exceptional value to our customers,” said Lee Newitt, chief executive officer at DCLI. “Equipping our entire DCL53 chassis fleet with GPS technology is a testament to our ongoing mission to lead the intermodal industry with innovative solutions and unparalleled fleet quality.”

BlackBerry Radar is an easy-to-install, asset monitoring solution for chassis, trailers, containers, and railcars, and provides near real-time information around location, cargo load status, motion, mileage, temperature, humidity, door open/close status, handbrake engaged status, and impact events through an intuitive dashboard. A device-agnostic platform that provides customers with a single pane of glass view for their asset management needs, with BlackBerry Radar, all data is transmitted and stored securely on a cloud platform, which maintains the privacy of user information at all times.

To find out more about BlackBerry Radar, visit www.blackberry.com/radar.

About BlackBerry

BlackBerry (NYSE:BB)(TSX: BB) provides enterprises and governments the intelligent software and services that power the world around us. Based in Waterloo, Ontario, the company’s high-performance foundational software enables major automakers and industrial giants alike to unlock transformative applications, drive new revenue streams and launch innovative business models, all without sacrificing safety, security, and reliability. With a deep heritage in Secure Communications, BlackBerry delivers operational resiliency with a comprehensive, highly secure, and extensively certified portfolio for mobile fortification, mission-critical communications, and critical events management.

©2025 BlackBerry Limited. Trademarks, including but not limited to BLACKBERRY and EMBLEM Design, QNX and the QNX logo design are the trademarks or registered trademarks of BlackBerry Limited, and the exclusive rights to such trademarks are expressly reserved. All other trademarks are the property of their respective owners. BlackBerry is not responsible for any third-party products or services.

About Direct ChassisLink, Inc. (“DCLI”)

DCLI is the largest provider of container chassis to the U.S. intermodal industry. Since 2009, when the company pioneered the exit of ocean carriers from the chassis business, we have generated consistent growth through expansion, acquisition, and innovation. We own, lease, and manage approx. 137,000 marine chassis and 152,000 domestic chassis with over 415 locations on or near key port facilities, depots, and intermodal hubs across the country. Since our founding, we have worked with motor carriers, ocean carriers, beneficial cargo owners, and domestic shippers to transform the way that chassis work within the intermodal supply chain. With a focus on equipment quality, operational efficiency, and delivering a great driver experience, our ultimate goal is to be the industry’s chassis partner of choice. To learn more about DCLI, please visit our website at www.dcli.com.

Media Contacts:

BlackBerry Media Relations
+1 (519) 597-7273
mediarelations@BlackBerry.com

DCLI Media Relations
Stacy Kirincic
AVP, Marketing
+1 (773) 793-0345
stacy.kirincic@dcli.com

Mike O’Malley
SVP Government and Public Relations, Human Resources
+1 (904) 314-2152
mike.omalley@dcli.com

SOURCE: BlackBerry Limited

View the original press release on ACCESS Newswire

Funding will be used for production and company growth in the US and abroad

INDIANAPOLIS, INDIANA / ACCESS Newswire / May 22, 2025 / Arrive AI (NASDAQ:ARAI), an autonomous delivery network anchored by patented AI-powered Arrive Points™, today announced that it has secured financial backing of up to $40 million from Streeterville Capital, LLC. Access to the capital coincided with Arrive AI’s public debut on Nasdaq on May15, 2025.

“This significant capital injection is one of the reasons we went to the public markets,” said Arrive AI CEO Dan O’Toole. “We celebrate the forward thinking Streeterville is leading with in their major commitment to our vision.”

Streeterville Capital is an investment firm with operations in Utah and Tennessee with investments in companies including Cingulate, the Marygold Companies and Damon Inc. Streeterville Capital President John Fife said he is intrigued with the vast potential of Arrive AI’s solution for package delivery issues like security and efficiency, and the cost savings that can be gleaned.

“This is an exciting answer to problems that are plaguing every industry. Dan and his crew really saw the future coming and worked quickly to meet needs that are starting to be seen around the world,” Fife said. “We’re excited to see how this plays out and are clearly bullish about Arrive AI.”

In 2014, O’Toole filed for his first patent for his concept of an AI-powered, smart mailbox capable of securely accepting packages delivered autonomously, beating similar filings from other potential competitors. Since then, he has built a global team, made multiple iterations and acquired complementary technology to refine the devices now known as “Arrive Points.” The company, which has amassed nearly 5,000 private investors and raised nearly $12 million, has largely generated capital via crowdsourcing. Now that Arrive AI is public a new chapter has begun.

-30-

About Arrive AI

Arrive AI‘s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com (http://www.arriveai.com/).

Media contact: Cheryl Reed, media@arriveai.com

Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com

Cautionary Note Regarding Forward Looking Statements

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements”

within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements (including statements related to the closing, and the anticipated benefits to the Company, of the private placement described herein) related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s Registration Statement for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the “Company”), comments on the new COVID Vaccine policy adopted by the US FDA.

The new FDA COVID Vaccine Booster Shots policy ^[1] is based on the findings that the groups that benefit from repeat of vaccination (i.e. booster shots) are the groups that are likely to be at risk of severe COVID disease from the virus. These groups include all adults over 65 years of age, and persons over 6 months of age that have one or more co-morbidity factors leading to a disposition towards severe COVID if infected.

The FDA policy notes that the benefit of repeat dosing of vaccine among people with low risk (i.e. healthy adults) is uncertain. As such, the FDA now will require randomized, placebo-controlled clinical trials that produce evidence of effectiveness in this healthy adults group if a vaccine is submitted for licensure to include this group.

In the past, the COVID vaccines were approved for all ages above 6 months. This resulted in CDC recommending the COVID vaccines for everyone. Yet, COVID vaccine uptake rate was only about 25% of the eligible persons in the last few years.

Over years of exposure, the population has built immunity due to multiple infections from ever-changing COVID variants as well as multiple vaccinations. An additional booster dose in such population would only make sense if a clear benefit can be proven.

“Evidence-based decision making about vaccine boosters policy for COVID is a welcome change over broadcast vaccine recommendation for all,” commented Anil R. Diwan, Ph.D., President and Executive Chairman of NanoViricides, adding, “This rational and scientific, non-dogmatic approach should go a long way towards restoring public trust in institutions that make decisions that affect peoples’ lives.”

The new policy brings the US FDA policy to be similar to the vaccination policies adopted in most developed countries. Even so, between 100 million to 200 million Americans are estimated to be eligible for boosters because of the broad definition for co-morbidity factors that put a person at high risk of severe COVID, which include obesity, diabetes, asthma, and even mood disorders.

“We believe that when a highly effective antiviral drug against COVID becomes available, the need for vaccination will decrease substantially,” said Dr. Diwan, adding, “Our broad-spectrum antiviral drug NV-387 is poised to become an important solution for multiple viral threats that emerge every season, including Influenzas, Coronaviruses, RSV, MPox, and possibly even Measles!”

About NanoViricides

NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

---

^[1] Vinay Prasad, M.D., M.P.H., and Martin A. Makary, M.D., M.P.H. “An Evidence-Based Approach to Covid-19 Vaccination”, New England J Med., published May 20, 20

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

OTTAWA, ON / ACCESS Newswire / May 22, 2025 / OakWood Designers & Builders, one of Ottawa’s most respected and enduring home construction firms, has been recognized with the 2025 Consumer Choice Award in the Home Builder category. This milestone achievement honours OakWood’s unparalleled legacy of craftsmanship, client-first design, and visionary use of technology that continues to set new benchmarks for the residential building industry in Canada’s capital.

Founded in 1956 by German master carpenter John Liptak Sr., OakWood started as a modest carpentry business and has since grown into a fourth-generation, family-run powerhouse. Today, under the leadership of Patricia Liptak-Satov and Angela Mallon, the company is celebrated for its award-winning Design + Build services, cutting-edge technology integration, and exceptional commitment to client satisfaction. From custom homes to large-scale renovations and multi-unit developments, OakWood continues to lead by example.

“It’s a tremendous honour to receive the Consumer Choice Award,” said Patricia Liptak-Satov, COO of OakWood. “This recognition reaffirms our team’s commitment to excellence at every stage of a project-from design and material selection to construction and post-completion care. We’re proud to have earned the trust of our clients, and we’re excited to keep raising the bar for what’s possible in home building.”

A Full-Service Design + Build Leader

OakWood offers a complete, vertically integrated approach to residential construction. Clients benefit from in-house architectural and interior designers, professional project managers, skilled trades, and Ottawa’s most advanced construction showroom experience. Its award-winning Design Centres-located in Ottawa South and Downtown-showcase thousands of premium materials, finishes, fixtures, and smart home technologies to help clients bring their visions to life.

Core offerings include:

• Custom homes with net-zero and energy-efficient options

• Full-home renovations and additions

• High-end kitchens and bathrooms

• Multi-unit developments

• Architectural design, permitting, and project management

Every project is supported by OakWood’s industry-leading client portal, which offers real-time updates, financial transparency, and milestone tracking-ensuring a stress-free experience from concept to completion.

A Technology-Driven Approach to Modern Building

What sets OakWood apart is not only its decades-long legacy, but also its commitment to innovation. The company is a national leader in smart home integration, sustainable building practices, and prefabrication solutions. OakWood was one of the first builders in Canada to offer Net-Zero Ready Homes, and it continues to lead the charge in green construction with eco-conscious designs that minimize environmental impact without compromising on luxury.

The firm’s use of virtual reality, 3D modeling, and AI-enhanced design tools further streamlines the process and allows homeowners to engage with their spaces before construction begins-enhancing confidence and satisfaction.

Award-Winning Excellence Recognized

The Consumer Choice Award is based on independent market research and community feedback. Winners are selected based on brand reputation, customer satisfaction, and industry performance. OakWood’s recognition as the top Home Builder in Ottawa highlights not only its exceptional output, but also its consistent ability to evolve and lead in a highly competitive market.

In addition to this latest honour, OakWood has received over 180 local, national, and international awards for design, innovation, and business excellence. The company has been recognized by the Greater Ottawa Home Builders’ Association (GOHBA), Ontario Home Builders’ Association (OHBA), and has achieved distinctions from the Better Business Bureau and Canadian Home Builders’ Association.

Looking Ahead: Building the Future of Home Living

As the residential landscape continues to shift, OakWood remains firmly focused on anticipating client needs and shaping the future of the industry. From expanding its sustainable building offerings to launching design initiatives that reflect Canada’s evolving lifestyles, the company is always several steps ahead.

“Our clients aren’t just building homes-they’re investing in better ways to live,” added Patricia. “That’s why we continue to innovate, hire the best people, and deliver work that exceeds expectations. This award is for them as much as it is for us.”

To learn more about OakWood Designers & Builders or to schedule a consultation, CLICK HERE or visit www.oakwood.ca.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

ADELAIDE, AUSTRALIA / ACCESS Newswire / May 21, 2025 / Barton Gold Holdings Limited (ASX:BGD) (Barton or the Company) advises that the attached announcement has been released to the market.

A copy of this announcement can be accessed on the ASX website, the investor section of Barton’s website, or directly by clicking here.

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold
Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.7Moz Au & 3.1Moz Ag JORC Mineral Resources (64.0Mt @ 0.83 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

Competent Persons Statement & Previously Reported Information
The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy ( AusIMM ), Australian Institute of Geoscientists ( AIG ) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource	Mr Dale Sims (Consultant)	AusIMM / AIG	Fellow / Member

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information
This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

* Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 4 March 2025. Total Barton JORC (2012) Mineral Resources include 909koz Au (30.8Mt @ 0.92 g/t Au) in Indicated category and 799koz Au (33.2Mt @ 0.75 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

LAS VEGAS, NEVADA / ACCESS Newswire / May 21, 2025 / ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ:ALTS)(FRA:5AR1), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, today announces June 2, 2025 as the record date for the previously announced transaction involving further steps in the Company’s formal separation of its healthcare assets, known as Alyea Therapeutics Corporation (“Alyea”). As previously announced, the Company has decided to separate its healthcare and fintech segments to allow each entity to concentrate on its unique business needs.

The Company expects that it will announce the scope and method of a partial or full disposition of its interests in Alyea, whether as a split-off or a spin-off or another related transaction, later this year, but wanted to provide its stakeholders and the market with a specific record date for such transaction. All record and beneficial holders of equity in the Company and all holders of equity underlying various securities of the Company on the record date, where applicable, will be able to participate in the distribution of Alyea in a transaction, the details of which are yet to be announced. No vote of the equity holders of the Company is required as of the date of this press release or as of the record date. The Company will advise its stakeholders and the market if a vote of the “record date security holders” of the Company will be required in connection with an Alyea distribution.

About ALT5 Sigma Corporation
ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation), provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Sigma has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is working on the separation of our biotech business that will move forward under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

About Alyea Therapeutics Corporation
Alyea, an ALT5 company, is developing innovative, actionable solutions intended to help end the opioid crisis. Alyea is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation’s history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also contains general statements relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies. This press release also contains statements that are forward-looking in respect of the expected future partial or full disposition of the Company’s interests in Alyea without specific=ty of the scope or methods thereof.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media Contact Investor Relations
IR@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp

View the original press release on ACCESS Newswire

Strategic media partnership will amplify AINOS’s brand and innovation story across major financial networks and digital platforms

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / AINOS, Inc. (NASDAQ:AIMD), a diversified biotech and AI-driven diagnostics company, has signed a long-form broadcast and commercial media agreement with New to The Street, a leading provider of televised investor communications. As part of the agreement, AINOS will be featured in monthly long-form interview segments and nationally broadcast commercials across:

• CNBC

• FOX Business

• Bloomberg Television

• New to The Street’s YouTube channel, with 2.51 million subscribers and growing

The content will spotlight AINOS’s leadership, product pipeline, and forward-looking strategy to a broad base of retail and institutional investors.

“We’re excited to partner with New to The Street to elevate our story at a time of rapid growth,” said [AINOS Executive Name/Title]. “With national TV exposure and recurring digital placement, this agreement provides a powerful platform to reach investors globally.”

New to The Street, known for its televised presence at the NYSE and Nasdaq MarketSite, has helped hundreds of emerging growth companies expand visibility through a combination of earned, sponsored, and digital media.

The AINOS campaign will also include a custom segment intro, with recurring broadcast features and cross-platform exposure across NTTS’s investor-focused ecosystem.

“We’re proud to welcome AINOS to our expanding lineup of innovators,” said Vince Caruso, CEO of New to The Street. “Their science-first approach and strategic outlook make them a natural fit for our audience and broadcast platforms.”

The first segment is scheduled to air in June 2025, with subsequent features rolling out monthly.

For media inquiries, contact:

Monica Brennan
Media Relations – New to The Street
monica@newtothestreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

LONDON, UNITED KINGDOM / ACCESS Newswire / May 21, 2025 / Feeding your dog or cat might be doing more damage to the planet than you think.

A new study has revealed that conventional meat-based pet food carries a largely unrecognized environmental cost – contributing significantly to land use, greenhouse gas (GHG) emissions, and climate breakdown. The review, just published, found that pet food production is closely tied to the livestock industry, which is responsible for at least one-fifth of annual global GHG emissions.

With the world’s pet population now approaching one billion animals, the impacts are no longer minor. In the United States alone, dog and cat diets account for 25-30% of the environmental toll of livestock farming. One analysis even found that a single medium-sized dog’s diet in Japan had a greater environmental footprint than the average Japanese person’s diet.

But experts say there’s a powerful – and practical – solution. Stated Billy Nicholles, the lead author, “Switching pets to nutritionally sound vegan diets significantly mitigates our dogs and cats’ environmental ‘paw prints.’ It’s a huge opportunity to reduce the environmental burden of our food system.”

The study examined 21 existing analyses of pet food sustainability and concluded that diet was the single largest factor driving environmental impacts. Protein choice was key: pet foods rich in animal ingredients were consistently linked to much larger environmental impacts.

By contrast, vegan pet diets – where formulated to be nutritionally sound – offered major reductions across all impact categories. If all pet dogs worldwide were fed a vegan diet, the resulting food energy savings could feed 450 million people, according to the study. Greenhouse gas savings would exceed the UK’s annual emissions.

“This offers huge potential,” said Professor Andrew Knight, co-author and veterinary expert. “Modern vegan pet foods are not only safe, but often healthier. And they’re vastly more sustainable.”

The report also pointed to emerging innovations like cultivated meat and precision-fermented proteins, which are beginning to enter the pet food market. These alternatives promise the taste and nutrition of meat without the massive environmental burden.

With consumer demand growing, the authors urge governments, brands, and the public to rethink what goes into pet food bowls. “Sustainable pet food isn’t just a niche trend,” said Nicholles. “It’s a climate solution hiding in plain sight.”

Contact Information

Billy Nicholles
Pet food researcher
billy@bryantresearch.co.uk
+44 7921461778

Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@murdoch.edu.au

SOURCE: Sustainable Pet Food Foundation

View the original press release on ACCESS Newswire

Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1’s upcoming IND submission for a rare disease indication

MIAMI, FLORIDA / ACCESS Newswire / May 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), an emerging leader in age-reversal science, today announced it has secured $3 million in equity financing, through a direct investment by The Bayshore Trust, the Company’s largest shareholder.

The transaction involved the purchase of 1 million restricted shares of the Company’s common stock at $3.00 per share, representing an 18% premium to Telomir’s closing share price of $2.54 on the date of execution. The transaction was structured as a straight restricted common stock transaction with no warrants, no discounts, and no convertible features.

This transaction follows a prior $1 million equity investment at $7.00 per share made on December 9, 2024, through The Starwood Trust-an entity affiliated with the Company’s largest shareholder – and complements an existing $5 million non-dilutive line of credit from the same affiliated group, which remains undrawn.

“We’ve now raised $4 million in equity and secured a $5 million credit line – all through affiliated entities on shareholder-friendly terms,” said Erez Aminov, Chairman and CEO of Telomir. “These investments included no warrants, no discounts, and no toxic structures. Every financing decision we make is grounded in a long-term view of shareholder value, and this raise reflects that discipline.”

From an operational standpoint, our first goal is to submit our IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way. We believe pursuing a rare disease indication gives us a strategic entry point to demonstrate clinical impact and build broader value.

Advancing a Growing Pipeline with Breakthrough Potential

Telomir is advancing two highly innovative drug candidates: Telomir-1, a first-in-class age-reversal molecule targeting the root causes of cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound designed to address the growing threat of drug-resistant infections.

Telomir-1: Reversing Aging, Treating Disease, and Extending Longevity

Telomir-1 is an oral small molecule that addresses five fundamental biological drivers of aging and chronic disease: mitochondrial dysfunction, oxidative stress, calcium imbalance, toxic metal accumulation (iron and copper), and telomere shortening.

In preclinical models, Telomir-1 has demonstrated:

• Reversal of the biological clock, improving both lifespan and health span

• Improvement of mitochondrial energy production in metabolically stressed cells

• Reduction of oxidative stress (ROS), a key contributor to age-related damage

• Correction of calcium signaling pathways associated with neurodegeneration and cell death

• Protection against metal-induced toxicity from iron and copper

• Telomere lengthening and stabilization to support cellular regeneration

Therapeutic potential has been demonstrated across several critical indications:

• Progeria: Telomir confirms lifespan restoration and normalization of accelerated aging in a preclinical model of Progeria, a rare genetic disorder causing rapid aging

• Type 2 diabetes: Telomir-1 reversed insulin resistance, lowered fasting glucose, and improved glucose homeostasis in zebrafish models

• Wilson’s disease: Telomir-1 protected cells from copper-induced toxicity, restoring mitochondrial function and reducing oxidative stress

• Oncology: In a prostate cancer mice model, Telomir-1 reduced tumor volume by approximately 50%

• Chemotherapy support: Co-administration with Paclitaxel prevented mortality in animals otherwise experiencing toxicity

• Retinal and neural protection: In vitro studies showed strong protection of human retinal cells from oxidative and metal stress conditions

These results support the advancement of Telomir-1 in multiple rare and high-value indications, including:

• Progeria and Werner Syndrome

• Wilson’s Disease

• Type 2 Diabetes

• Autism Spectrum Disorder (ASD)

• Spasmodic Dysphonia (SD)

• Age-related Macular Degeneration (AMD)

Telomir plans to engage with the FDA through the Rare Disease Endpoint Advancement (RDEA) Pilot Program, which supports the development of novel clinical endpoints for underserved conditions. In parallel, the Company is advancing a rare disease indication aligned with Telomir-1’s mechanism of action to efficiently generate early human efficacy data and support broader clinical development.

Telomir-Ag2: Stabilized Silver(II) for Drug-Resistant Infections

Telomir-Ag2 is a novel Silver(II) complex stabilized using Telomir’s proprietary chelation platform. Silver(II) has historically shown strong antimicrobial potential but has remained clinically impractical due to its instability-until now.

Preclinical studies demonstrate that Telomir-Ag2 is active against:

• Escherichia coli

• Pseudomonas aeruginosa

• Enterococcus faecalis

• Staphylococcus aureus

• Methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA)

Key features include:

• Superior antimicrobial performance over Silver(I) in minimum inhibitory concentration (MIC) assays

• No sulfa-based compounds, minimizing allergic and cytotoxic risks

• Broad potential as a topical product across burn treatment, wound care, and surgical infection prevention

Telomir-Ag2 addresses a growing global market projected to exceed $30 billion across antimicrobial dressings, hospital-acquired infection prevention, and wound care.

“Telomir-Ag2 may be the first stabilized Silver(II) compound viable for medical use,” said Dr. Itzchak Angel, Chief Scientific Advisor of the Company. “It’s broad-spectrum activity, especially against resistant strains, represents a major advancement in antimicrobial science.”

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

Acquisition strengthens nationwide telehealth coverage, advancing access to critical and specialized care for hospitals nationwide

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Equum Medical, one of the nation’s leading providers of acute telehealth-enabled clinical workforce solutions, today announced it has acquired the clinical health services of VeeOne Health, including its Tele-Psychiatry, Tele-Neurology, Tele-Infectious Disease (Tele-ID), Tele-Pulmonary and Tele-ICU service lines. This strategic acquisition expands Equum’s comprehensive telehealth offerings across the care continuum and reinforces its recognized market leadership in acute care telehealth. The combined entity now will support physician service coverage in over 200 hospitals and post-acute facilities nationwide.

With the addition of VeeOne’s capabilities, Equum accelerates its mission to improve healthcare access and outcomes for hospitals and health systems. Tele-Psychiatry services will enable partner hospitals to provide 24/7 emergency and acute psychiatric care virtually, addressing the nationwide shortage of mental health specialists. Likewise, Tele-Neurology services (including on-demand stroke neurologists and other neuro-specialists) will allow rapid neurological consultations in emergency and acute settings, ensuring patients receive timely expert care regardless of location.

Dr. Corey Scurlock, CEO and Founder of Equum Medical, stated, “The acquisition of VeeOne Health’s services represents an exciting opportunity to continue expanding the reach and depth of Equum’s acute care telehealth offerings. By adding these critical service lines, Equum further solidifies its position as a comprehensive partner to hospitals nationwide. We are committed to ensuring that our expanded services bring even greater value to our customers and improved outcomes for patients.”

Ijaz Arif, CEO of VeeOne Health, added, “Equum Medical is an ideal home for VeeOne’s clinical services portfolio. Over the years, we have built robust telehealth programs that have made a real impact for our clients. Joining forces with Equum – a market leader in acute telehealth – means our customers will now benefit from a full spectrum of high-acuity telehealth solutions under one roof. Equum’s commitment to clinical quality and innovation mirrors our own, and we are confident that together, we will continue to provide exceptional virtual care services to healthcare organizations nationwide. This is a win for our clients and for the future of telehealth.” Following this transaction, VeeOne Health Inc. will continue to devote its focus on leading innovation in the virtual healthcare market, supporting healthcare organizations worldwide through its AI-based products to enhance patient care in areas such as remote patient monitoring (RPM), hospital at home, acute inpatient care, ambulatory services, care coordination, and virtual nursing.

Strategic Rationale and Impact:

The acquisition comes at a pivotal time in healthcare, as hospitals face persistent workforce shortages and a rising demand for specialized care. By integrating VeeOne’s tele-specialty services, Equum Medical strengthens its position as a one-stop solution for hospitals seeking to augment staff and expand specialist coverage through virtual care. Equum’s expanded service portfolio is designed to address hospital needs addressing patient flow and through this announcement now spans serviceability pillars of both Access and Capacity. The Access Suite including multi-specialty services of Tele-Stroke, Tele-Neurology, Tele-Psychiatry, Tele-Pulmonology, Tele-Infectious Disease, Tele-Cardiology, Tele-Nephrology, and high acuity physician services of Tele-Critical Care, and Tele-Hospitalist and a Capacity Suite including virtual nursing, virtual safety sitter and observation programs, and telemetry monitoring with extensions into post-acute with Remote Patient Monitoring.

Market Leadership:

This acquisition also highlights the strength of Equum Medical’s leadership team and market strategic position. Equum is included in Becker’s Hospital Review Top Telehealth Companies to Know and prior to the global HIMSS event in Las Vegas in March 2025, Equum Medical was recognized as the #1 Vendor by market research firm Black Book Market Research in Tele-Critical Care and Virtual Nursing Solutions as well as overall Outsourced Virtual Clinician Services. For the executive team, Dr. Scurlock is a national speaker at such events as American Telemedicine Association Annual Conference (NEXUS) and National Rural Health Association (NRHA) and was recognized as one of the Top Digital Health Leaders by Slice of Healthcare for his impactful work in virtual care while Kristen Lawton, MSN, RN Equum’s Chief Nursing Officer, was honored among Becker’s “Women in Health IT to Know” (2024). Under their leadership, Equum has cultivated a culture of clinical excellence and innovation – a culture that will extend to the integration of VeeOne’s services.

Media Contact:

Karsten Russell-Wood
Chief Marketing & Experience Officer
karsten.russell-wood@equummedical.com
(T) 410-409-7376

Press Kit & Further Information: Please visit the Equum Medical website at www.equummedical.com or contact our media relations team (marketing@equummedical.com) for more details.

About Equum Medical: Equum Medical is a technology-enabled inpatient clinical services company recognized for its comprehensive acute care portfolio, now with expanded coverage in Tele-Neurology, Stroke and Psychiatry. Equum leverages advanced telehealth technologies to enhance clinical access and optimize healthcare delivery across hospitals in the United States. By addressing workforce challenges and improving operational efficiency, Equum Medical empowers healthcare systems to elevate patient care, optimize leadership, and achieve positive clinical, operational, and financial outcomes. For more information, visit www.equummedical.com.

About VeeOne Health: Based in Roseville, CA, VeeOne Health is a global leader in the Virtual Care technology, and operations. Founded in 2016, VeeOne Health has the most advanced telemedicine solutions for the entire continuum of care – from acute care settings to outpatient and remote patient monitoring. For more information about VeeOne Health’s vision for the future of telemedicine see https://veeonehealth.com/

SOURCE: Equum Medical

View the original press release on ACCESS Newswire